PathAI Press & Releases

PathAI presents results at The AASLD Liver Meeting 2021 showing that panel scoring of NASH histological features can reduce bias and increase reproducibility
Research study shows high concordance in scores within panels of three NASH-trained pathologists and between independent panels

PathAI Reports that Its ML-based NASH Drug Discovery Tool May Identify Clinical Trial Responders Based on Post-Hoc Analysis of Bristol Myers Squibb’s FALCON 1 Study at The Liver Meeting 2021
Post-hoc evaluation of liver biopsies from patients in the Bristol Myers Squibb sponsored FALCON 1 study by AI-based histologic measurement of NASH (nonalcoholic steatohepatitis; AIM-NASH) drug development tool (DDT) suggests that clinical trial endpoints may have been met and shows treatment-associated improvements in key liver tissue features not identified by manual assessment.

PathAI Composite PD-L1 and AI-powered CD8+ Topology Biomarker May Improve Prediction of Immuno-Oncology Treatment Response in Patients with Melanoma at the Society for Immunotherapy of Cancer Meeting 2021
Retrospective analysis of digitized immunohistochemistry-stained tumor biopsies of advanced melanoma patients treated with nivolumab monotherapy or the combination of nivolumab plus ipilimumab collected in a clinical trial revealed a subpopulation of patients who were PD-L1 negative (<1%) that displayed a CD8+-excluded tumor spatial pattern benefited significantly from the drug combination treatment (nivolumab and ipilimumab) (P = 0.002) compared with PD-L1 negative patients with a CD8+-inflamed tumor spatial pattern.

PathAI and Novo Nordisk present AI-powered scoring showing significant reduction of fibrosis following semaglutide treatment in patients with NASH
AI and manual pathology measurements show efficacy of semaglutide over placebo in phase 2 clinical trial, with AI continuous scoring providing quantitative insight into histological changes

PathAI Welcomes Two New Executives as it Strengthens its Biopharma Business Leadership Team
Saumya Pant, Ph.D. and Jiayi Hao join PathAI’s Executive Team to accelerate growth and innovation in its Biopharma business.

PathAI Announces Strategic Partnership with Roche to Enable Development and Distribution of Digital Pathology Diagnostics
Partnership brings together PathAI’s market-leading artificial intelligence-powered technology and Roche’s assay development and digital pathology capabilities to offer an integrated diagnostic solution for laboratories and biopharmaceutical clients.

PathAI and Summit Clinical Research Launch a Comprehensive NASH Clinical Trial Services Solution to Optimize Trial Success
The collaboration provides sponsors with an innovative offering tailored to NASH sponsors featuring trial design, site activation and patient enrollment, wet lab, diagnostic, and AI-pathology deployment services.

PathAI enters into clinical diagnostics through acquisition of Poplar Healthcare Management
PathAI makes investment in a leading national CAP/CLIA lab, advancing their capabilities for clinical research and directly serving the needs of patients.

Dr. Eric Walk Joins PathAI as Chief Medical Officer
Dr. Walk brings over 20 years’ experience successfully leading medical and scientific affairs teams to accelerate the development of next generation therapeutics and advanced diagnostic tools.

PathAI to Present Machine Learning-Based Drug Development Tool For Assessment of Nonalcoholic Steatohepatitis Histopathology at the International Liver Congress 2021
PathAI’s ML-based drug development tool can enable accurate and reproducible assessment of clinical trial enrollment criteria and clinical trial endpoints

PathAI to Present Machine Learning-based Quality Control Tool for HER2 Testing in Breast Cancer at the American Society of Clinical Oncology Virtual Scientific Program 2021
Collaboration to produce a machine learning (ML)-based tool that automatically analyzes images of HER2 immunohistochemistry (IHC)-stained tissue slides and reports metrics that can be used to monitor the quality of HER2 IHC testing in clinical trials

PathAI and Genentech Present on AI-Powered Pathologic Response Assessment in NSCLC at the American Society of Clinical Oncology Virtual Scientific Program 2021
Application of PathAI's machine learning (ML) models to data from the Genentech-sponsored LCMC3 trial showed that model calculations of pathologic response (PathR) in non-small cell lung cancer (NSCLC) were robust and suggest that these models have the potential to support pathologists assessing PathR in clinical trials and in practice.

PathAI Announces Completion of $165 Million Financing for Advancing Medicine with AI-powered Pathology
Led by D1 Capital Partners and Kaiser Permanente, capital will be used to continue acceleration of clinical research capabilities and expand commercial footprint.

PathAI ML Models Based on Human Interpretable Features Predict Clinically-Relevant Molecular Phenotypes Across Cancers
PathAI developed a machine learning (ML) model-based pipeline to predict tumor molecular phenotypes from hematoxylin and eosin (H&E) stained biopsies across 5 different tumor types.

PathAI and Labcorp Broaden Strategic Collaboration to Accelerate Use of AI-Powered Pathology
Integrating AI-Powered Pathology into Drug Development and Clinical Testing of Oncology and Other Diseases

PathAI Machine Learning Models Reveal Treatment-Induced Changes in the Non-Small Cell Lung Cancer Tumor Microenvironment in Samples from the LCMC3 Study
Preliminary results from a collaboration between PathAI and Genentech are presented at WCLC 2020, showcasing the application of PathAI’s ML models to tissue samples from LCMC3, a clinical trial of neoadjuvant atezolizumab (anti-PD-L1) in patients with resectable stage IB to select IIIB non-small cell lung cancer (NSCLC), (NCT02927301).

PathAI Present Machine Learning Models that Predict the Homologous Recombination Deficiency Status of Breast Cancer Biopsies at the 2020 SABCS
Artificial intelligence (AI)-powered machine learning (ML) models were trained to identify homologous recombination deficiency (HRD) directly from hematoxylin and eosin (H&E)-stained breast cancer tumor biopsy slides from the cancer genome atlas (TCGA), and performed with high accuracy.

PathAI and Gilead Report Data from Machine Learning Model Predictions of Liver Disease Progression and Treatment Response at AASLD’s The Liver Meeting 2020
Application of artificial intelligence (AI)-powered digital pathology to clinical trial biopsies reveals changes in cells, tissue, and gene expression associated with the pathogenesis and progression of nonalcoholic steatohepatitis (NASH) and chronic hepatitis B virus infection (CHB), that can be used to develop novel, sensitive, and accurate methods to evaluate liver biopsies and potentially monitor disease.

PathAI & Gilead Present Research at ILC 2020 Demonstrating AI Models Accurately and Reproducibly Assess Treatment Response and Disease Progression across Liver Disorders
PathAI’s artificial intelligence (AI)-powered pathology models were applied to liver biopsies obtained in Phase 2 and 3 clinical trials investigating Gilead therapeutics for the treatment of patients with chronic hepatitis B virus (HBV) infection, primary sclerosing cholangitis (PSC), or nonalcoholic steatohepatitis (NASH), and identified histopathologic features that correlated with treatment response and disease progression.

PathAI and Bristol Myers Squibb find Positive Association of Digital PD-L1 Expression with Outcomes in nivolumab-treated Patients in an Exploratory analysis
Digital analysis shows higher sensitivity for PD-L1 expression and accurate detection of low-level PD-L1 expression in patients compared to manual reading

PathAI demonstrates the potential of AI-based Characterization of the Tumor Microenvironment at ASCO
AI-powered analysis provides quantitative measurements of human interpretable features in the tumor microenvironment

PathAI Appoints Biopharma Executive and Digital Pathology Leader Michael Montalto, Ph.D., as Chief Scientific Officer
Former VP of Translational Sciences at Bristol-Myers Squibb joins PathAI Executive Team

PathAI and Gilead Show AI-Powered Pathology Research Models Accurately Interpret Liver Histology in Patients with NASH at AASLD 2019
Machine learning-based analyses of phase 3 trial provide quantitative assessments of liver histology and highlight heterogeneity of pathology in NASH

PathAI and Bristol-Myers Squibb to Showcase Results From First AI-Powered Analysis of PD-L1 Expression Across Three Phase 3 Trials at SITC 2019
AI-based approaches accurately quantified PD-L1 expression on tumor and immune cells and similarly predicted patient response compared to manual assessment

PathAI Announces Strategic Investment from Merck Global Health Innovation Fund and Bristol-Myers Squibb to complete $75M Series B Funding
Backing by leading immuno-oncology companies underscores the broad potential for digital pathology and strength of PathAI

PathAI Announces Strategic Investment from LabCorp
Growing Relationship Between PathAI and LabCorp Will Help Advance the Clinical Development of Artificial Intelligence for Use with Digital Pathology

PathAI Secures $60M in Series B Funding Led by General Atlantic and Existing Investor General Catalyst
Computational Pathology Leader Plans to Accelerate Industry Impact

PathAI Earns ISO 27001 Security Certification
Digital Pathology Leader Elevates Privacy and Security Standards.

PathAI Earns Major Quality Certification, Expands Executive Team with Regulatory Expertise
Digital Pathology Leader paves way to regulated medical devices to help treat cancer